[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351826-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351826-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","primary-tumor-associated-loss-of-the-y-chromosome-and-clinical-outcome-in-metastatic-colorectal-cancer","Primary Tumor-Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer","","Alterations of the Y chromosome occur frequently in solid tumors, but their biological and clinical meaning in metastatic colorectal cancer remains unclear. This study retrospectively evaluates primary tumors from 91 male patients, assessing tumor loss of the Y chromosome using a droplet digital PCR assay and examining links to clinicopathological features, KRAS/BRAF mutations, and survival. Exploratory TCGA-COAD/READ analyses integrate Y copy-number signal, mutations, and survival. Tumor LoY shows no association with key molecular factors, while overall survival is longer in LoY-positive cases.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/primary-tumor-associated-loss-of-the-y-chromosome-and-clinical-outcome-in-metastatic-colorectal-cancer/351826/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/primary-tumor-associated-loss-of-the-y-chromosome-and-clinical-outcome-in-metastatic-colorectal-cancer/351826.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was tumor loss of the Y chromosome (LoY) measured in this study?","Question",{"text":63,"@type":64},"Tumor LoY status was assessed using a droplet digital PCR–based assay on primary tumor samples from 91 male patients with metastatic colorectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Is tumor LoY associated with KRAS/BRAF mutations or microsatellite instability?",{"text":68,"@type":64},"No. Tumor LoY was not associated with age, microsatellite instability status, or KRAS or BRAF mutations.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical outcome differences were observed between LoY-positive and LoY-negative tumors?",{"text":72,"@type":64},"Progression-free survival did not differ by LoY status, while overall survival was longer in patients with LoY-positive tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351826,1790243745,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Genes, Chromosomes and Cancer  \nRESEARCH ARTICLE  OPEN ACCESS   \nPrimary Tumor-Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer  \nAnaëlle Isnard1,2 | Marie Decraecker2,3 | Benjamin Fernandez2,4 | Denis Smith3 | Pierre Dubus1,2 | Sandrine Dabernat2,5 | Olivier Mansier6,7  | Samuel Amintas1,2   \n1CHU Bordeaux, Tumor Biology and Tumor Bank Laboratory, Pessac, France | 2BRIC (BoRdeaux Institute of Oncology), INSERM, University of Bordeaux, Bordeaux, France | 3Oncology Unit, Haut Lévêque Hospital, University Hospital Center of Bordeaux, Pessac, France | 4CHU Bordeaux, Colorectal Digestive Surgery Department, Bordeaux, France | 5CHU Bordeaux, Biochemistry Laboratory, Bordeaux, France | 6CHU Bordeaux, Hematology Laboratory, Bordeaux, France | 7Biology of Cardiovascular Diseases, INSERM, University of Bordeaux, Pessac, France  \nCorrespondence: Samuel Amintas ([samuel.amintas@u-bordeaux.fr](samuel.amintas@u-bordeaux.fr))  \nReceived: 9 December 2025 | Revised: 29 May 2026 | Accepted: 2 June 2026  \nKeywords: biomarker | chromosomal instability | colorectal cancer | KRAS | loss of Y chromosome | survival  \nABSTRACT  \nBackground: Alterations ofthe Y chromosome are frequent events in solid tumors, yet their biological and clinical significance remains incompletely understood. In colorectal cancer (CRC), recent studies have suggested context-dependent roles of Y-linked genes in tumor progression, while the impact of tumor-associated loss of the Y chromosome (LoY) in metastatic disease has not been clearly established.  \nMethods: We retrospectively analyzed primary tumor samples from 91 male patients with metastatic CRC treated at a single institution. Tumor LoY status was assessed using a droplet digital PCR–based assay. Associations between LoY, clinicopathological characteristics, KRAS/BRAF mutation status, and patient outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated. Exploratory analyses of TCGA-COAD/READ data were performed using chromosome Y copynumber segment data, mutation data, and survival information.  \nResults: Tumor LoY was detected in 46 cases (50.5%) and was more frequent in rectal cancers (p = 0.038) . LoY was not associated with age, microsatellite instability status, KRAS or BRAF mutations. While PFS did not differ according to LoY status, OS was longer in patients with LoY-positive tumors (p = 0.046) . In multivariable analysis, LoY showed a non-significant trend toward improved OS (HR = 0.52, 95% CI: 0.25–1.10; p = 0.07). In exploratory TCGA analyses, chromosome Y copy-number signal did not significantly differ between colon and rectal cancers, but lower chromosome Y signal was associated with worse OS, particularly in TCGA-COAD after adjustment for age and KRAS/BRAF status.  \nConclusions: LoY is a frequent chromosomal alteration in metastatic CRC and appears enriched in rectal primary tumors in our cohort. Its association with clinical outcome may depend on disease stage, molecular background, and analytical methodology. These findings support further investigation of Y chromosome loss as a context-dependent biomarker in CRC.  \n1 | Introduction  \nSex differences between males and females can be detected early in life. They are also present later, even to a much greater extent, affecting adulthood across a wide spectrum of  \nbiological and phenotypic characteristics [1] . Sex-related biological differences are linked to multiple parameters, mainly hormonal influences, and sex chromosome–linked genetic factors. Beyond hormonal influences, sex chromosomes themselves represent a major source of genetic asymmetry between  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Genes, Chromosomes and Cancer published by Wiley Periodicals LLC.  \nGenes, Chromosomes and Cancer, 2","cbCaifSOg316xU4C","https://ap.wps.com/l/cbCaifSOg316xU4C","pdf",834398,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"How was tumor loss of the Y chromosome (LoY) measured in this study?\",\"answer\":\"Tumor LoY status was assessed using a droplet digital PCR–based assay on primary tumor samples from 91 male patients with metastatic colorectal cancer.\"},{\"question\":\"Is tumor LoY associated with KRAS/BRAF mutations or microsatellite instability?\",\"answer\":\"No. Tumor LoY was not associated with age, microsatellite instability status, or KRAS or BRAF mutations.\"},{\"question\":\"What clinical outcome differences were observed between LoY-positive and LoY-negative tumors?\",\"answer\":\"Progression-free survival did not differ by LoY status, while overall survival was longer in patients with LoY-positive tumors.\"}]","Primary Tumor-Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer | PDF",1790096171,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbd41f2faa8f3e2e47deb94e6b086e37.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05b12a3bed8d64a9bb9b50ece5d5bd02.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25d27777a53a7b9baa6e11a82dbd01d6.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3b715543f1bb60aa641f27373edca74.webp",980,1287]